Smith Brendan 4
4 · CRISPR Therapeutics AG · Filed Oct 12, 2022
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-10-07+14,000→ 14,000 totalExercise: $61.65Exp: 2032-10-07→ Common Shares (14,000 underlying)
Footnotes (1)
- [F1]This option was granted on October 7, 2022 with respect to 14,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022.